Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer

SYDNEY, Australia and MINNEAPOLIS, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company, announces a contract for the latest release of its corporate health program, ilumen™.

ilumen™ is unique to the corporate health market as it integrates unique and proprietary objective biometrics with subjective assessments. Users can access and monitor this data from their personal devices, measuring and tracking biometrics through the use of wearable technology over a period of time.

ilumen™ will be offered to 8,000 personnel of a large employer in Australia over a six-week period commencing October 2018.  The contract is valued at $30,000 for the six-week engagement. 

The contract confirms the market acceptance of Medibio’s corporate wellness technology.

Senior Vice President of Corporate Health at Medibio, Jennifer Solitario, says, “We are pleased to be partnering with a market leading organisation to deliver ilumen to their Australian workforce.  ilumen offers the organisation an opportunity to better understand their staff's mental health and well-being. They will soon have more insight into how they can create enlightened strategies to maintain a healthy, happy, high-performance workforce.”  

About Medibio Limited
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.